Financial Snapshot

Revenue
$0.00
TTM
Gross Margin
Net Earnings
-$9.163M
TTM
Current Assets
$10.03M
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
566.08%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
$7.071M
Q3 2024
Cash
Q3 2024
P/E
-3.117
Nov 29, 2024 EST
Free Cash Flow

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019
Revenue $0.00 $0.00 $0.00 $0.00 $0.00
Cost Of Revenue
Gross Profit
Gross Profit Margin

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019
Selling, General & Admin $5.729M $5.649M $2.632M $818.0K $899.0K
YoY Change 1.42% 114.63% 221.76% -9.01%
% of Gross Profit
Research & Development $5.667M $4.301M $3.039M $2.386M $2.997M
YoY Change 31.76% 41.53% 27.37% -20.39%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $11.40M $9.950M $5.671M $3.204M $3.896M
YoY Change 14.53% 75.45% 77.0% -17.76%
Operating Profit -$11.40M -$9.950M -$5.671M
YoY Change 14.53% 75.45%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019
Interest Expense $108.0K $57.00K -$834.0K -$587.0K $63.00K
YoY Change 89.47% -106.83% 42.08% -1031.75%
% of Operating Profit
Other Income/Expense, Net $1.164M $61.00K $119.0K -$7.000K -$6.000K
YoY Change 1808.2% -48.74% -1800.0% 16.67%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019
Pretax Income -$10.23M -$9.889M -$6.324M -$3.798M -$3.839M
YoY Change 3.47% 56.37% 66.51% -1.07%
Income Tax
% Of Pretax Income
Net Earnings -$10.23M -$9.889M -$6.324M -$3.798M -$3.839M
YoY Change 3.47% 56.37% 66.51% -1.07%
Net Earnings / Revenue
Basic Earnings Per Share -$0.99 -$1.09 -$1.21
Diluted Earnings Per Share -$0.99 -$1.09 -$1.212M -$453.0K -$457.9K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019
Cash & Short-Term Investments $1.173M $6.440M $15.19M $1.795M $2.104M
YoY Change -81.79% -57.61% 746.35% -14.69%
Cash & Equivalents $1.173M $4.391M $15.19M $1.795M $2.104M
Short-Term Investments $0.00 $2.049M
Other Short-Term Assets $293.0K $825.0K $1.089M $115.0K $162.0K
YoY Change -64.48% -24.24% 846.96% -29.01%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.466M $7.265M $16.28M $1.910M $2.266M
YoY Change -79.82% -55.38% 752.41% -15.71%
Property, Plant & Equipment $0.00 $6.000K
YoY Change -100.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $4.000K $4.000K
YoY Change 0.0%
Total Long-Term Assets $0.00 $0.00 $6.000K $4.000K $4.000K
YoY Change -100.0% 50.0% 0.0%
Total Assets $1.466M $7.265M $16.29M $1.914M $2.270M
YoY Change
Accounts Payable $561.0K $534.0K $525.0K $162.0K $538.0K
YoY Change 5.06% 1.71% 224.07% -69.89%
Accrued Expenses $614.0K $568.0K $413.0K $311.0K $232.0K
YoY Change 8.1% 37.53% 32.8% 34.05%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $2.650M $0.00
YoY Change -100.0%
Long-Term Debt Due $0.00 $117.0K $0.00
YoY Change -100.0%
Total Short-Term Liabilities $1.175M $1.102M $938.0K $4.096M $805.0K
YoY Change 6.62% 17.48% -77.1% 408.82%
Long-Term Debt $0.00 $0.00 $0.00 $23.00K $0.00
YoY Change -100.0%
Other Long-Term Liabilities $3.291M
YoY Change
Total Long-Term Liabilities $3.291M $0.00 $0.00 $23.00K $0.00
YoY Change -100.0%
Total Liabilities $4.466M $1.102M $938.0K $4.119M $805.0K
YoY Change 305.26% 17.48% -77.23% 411.68%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019
Basic Shares Outstanding 10.29M shares 9.052M shares 5.217M shares
Diluted Shares Outstanding 10.29M shares 9.052M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $28.562 Million

About RenovoRx, Inc.

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapy platform to deliver chemotherapy. The company is headquartered in San Jose, California and currently employs 8 full-time employees. The company went IPO on 2021-08-17. The firm is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.

Industry: Pharmaceutical Preparations Peers: ABEONA THERAPEUTICS INC. Theriva Biologics, Inc. ATHERSYS, INC / NEW HUMANIGEN, INC YIELD10 BIOSCIENCE, INC. Tempest Therapeutics, Inc. NANOVIRICIDES, INC. ORGANOVO HOLDINGS, INC. KINETA, INC./DE